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Hemopericardium and subsequent tamponade is an insidious
complication of cather ablation procedures for atrial ﬁbrilla-
tion (AF).
Case report
An 84-year-old woman was admitted for catheter ablation of
long-standing, permanent AF. Her previous medical history
consisted of long-standing arterial hypertension and persis-
tent AF diagnosed 3 years ago. She had undergone circum-
ferential pulmonary vein (PV) isolation (ie, linear ablation
around the PV antra with subsequent veriﬁcation of PV
isolation) and repeat ablation of a macroreentrant atrial
tachycardia around the left superior PV. She had remained
in sinus rhythm for 2 months postablation, and paroxysmal
AF was detected after cessation of amiodarone therapy. On
admission, clinical examination was unremarkable. She was
in sinus rhythm, her blood pressure was 130/90 mm Hg, and
echocardiography revealed normal left ventricular ejection
fraction (65%), left atrial diameter of 32 mm, and grade I
mitral and tricuspid regurgitation. She had no signs of
myocardial hypertrophy or pericardial thickening. Her med-
ications consisted of irbesartan/hydrochlorothiazide, biso-
prolol, and low-dose aspirin. Her warfarin had been replaced
with subcutaneous enoxaparin 3 days ago, and her interna-
tional normalized ratio was 1.1.
She was taken to the electrophysiology laboratory for
circumferential PV isolation of all PVs and ganglionated
plexi ablation, according to our standard protocol.1 Trans-
septal puncture was performed at a high atrial septum site,
and difﬁculty was encountered in crossing the septum, which
had become ﬁbrosed after the previous 2 procedures.
Immediately afterward and before heparin was given, the
patient felt unwell. She became relatively hypotensive (80/50
mm Hg), and clinical signs of tamponade were obvious.
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pericardial effusion, with impaired right ventricular ﬁlling
and mitral ﬂow velocity paradoxus. Pericardiocentesis was
attempted immediately under ﬂuoroscopic and echocardio-
graphic guidance, without success. Although the needle was
clearly within the pericardial space, no blood was drawn. An
emergency thoracotomy was performed, which revealed a
large clot within the pericardium adjacent to the lateral wall
of the left atrium and left ventricle, without ongoing
bleeding. The patient experienced immediate relief and
recovered uneventfully. Subsequent thrombophilia testing,
including factor V Leiden and prothrombin mutations, and
antiphospholipid antibodies revealed a borderline lupus
anticoagulant, without anticardiolipin and anti–β2-glycopro-
tein-1 antibodies (Table 1).2,3 The patient refused further
ablation and was placed on oral anticoagulation.Discussion
Even though ablation procedures have evolved to offer
increased success rate and reduced complications, hemor-
rhagic events remain an insidious complication. Among the
complications, the development of hemopericardium and
subsequent tamponade has been documented in approxi-
mately 1.2% of patients.4–6 In most cases, pericardiocentesis
and percutaneous drainage can provide effective treatment;
however, surgical intervention is sometimes needed, mainly
in the setting of uncontrolled pericardial bleeding.
Two underrecognized clinical entities that can lead to
tamponade and can be difﬁcult to identify with transthoracic
echocardiography as well as to treat with percutaneous
drainage are loculated hemopericardium (eg, in patients with
prior cardiac surgery and preexisting intrapericardial adhe-
sions) and coexisting huge pleural effusion.7,8 Immediate
pericardial thrombus is an extremely rare possibility because
small amounts of blood in the pericardial space do not result
in immediate clot formation.8 In fact, intracavitary blood has
long been known to be incoagulable,9 and even though
evidence for pericardial effusions does not exist, extrapola-
tion of hemothorax characteristics suggests that hemoper-
icardium is deﬁbrinated and thrombocytopenic, and contains
elevated levels of D-dimers.10 Accordingly, early develop-
ment of pericardial thrombus is an unlikely ﬁnding.pen access article under the CC BY-NC-SA license
http://dx.doi.org/10.1016/j.hrcr.2014.12.002
KEY TEACHING POINTS
 Pericardial thrombus is an extremely rare
possibility, but it may occur and, if accompanied by
tamponade physiology, would require surgical
evacuation.
 Female gender and older age confer increased
complication risk.
 Repeat transseptal punctures are associated with a
higher risk for cardiac tamponade because of
scarring of the previously perforated septum.
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nade physiology, would require surgical evacuation.8
Our case also emphasizes the need for thorough prepro-
cedural assessment of patient characteristics predisposing to
complications and appropriate adaptations of treatment
strategy. Several periprocedural complications have been
associated with female gender, older age, and procedural
complexity,11 and previous ablation procedures and repeat
transseptal punctures carry a 3-fold higher risk for cardiac
tamponade because of scarring of the previously perforated
septum.5 When a difﬁcult transseptal puncture is anticipated,
intracardiac echocardiography has been shown to reduce
the rate of hemopericardium and tamponade to 0.25%.11Table 1 Thrombophilia testing
1. Blood cell count with peripheral smear, hepatic and renal
function, and serum protein electrophoresis.
2. Genetic testing for factor V Leiden and prothrombin G20210A
mutations, especially if an inherited thrombophilia is suspected.
3. Antiphospholipid antibodies (eg, lupus anticoagulant,
anticardiolipin antibodies, anti–β2-glycoprotein-1 antibodies).
Testing for antiphospholipid antibodies requires conﬁrmation
12 weeks after an initial positive result.
4. Antithrombin, protein C, and protein S, at least 6 weeks after
the event.
Note: Direct leukocyte genomic DNA testing for factor V Leiden and
prothrombin G20210A mutations is unaffected by anticoagulation therapy.
Heparin therapy can lower antithrombin activity and antigen levels and can
impair interpretation of clot-based assays for a lupus anticoagulant. A delay
of at least 5 days after heparin is stopped before testing usually is feasible.
Warfarin therapy reduces the activity and antigen levels of vitamin K–
dependent factors, including proteins C and S (up to 6 weeks). Non–vitamin-
K-dependent oral anticoagulants (NOACs) may cause false-positive lupus
anticoagulant (dilute Russell viper venom time) test results and falsely low
antithrombin activity. Testing should be delayed until the effects of warfarin
or NOACs therapy have resolved.Furthermore, on occasion a higher puncture position or a
larger-curve Brockenbrough needle may be needed.12 In the
presence of a dilated left atrium, a technique used in mitral
valvuloplasty may be of help.13 The issue of uninterrupted
anticoagulation with either a vitamin K antagonist or Xa
inhibitor,14,15 which appears to be safer than bridging to
heparin, or no anticoagulation 2–3 days before ablation also
may be raised. However, the limited experience of just 1 case
does not allow any deﬁnitive conclusions in this respect.
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